Company snapshot
- Ticker
- ABOS
- Exchange
- NMS
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $15.64M
- Employees
- 60
- Currency
- USD
- Website
- https://acumenpharm.com
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a…
Latest coverage
- Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
November 5, 2026